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Use of the Progestin Challenge Test in Diagnosing Amenorrhea: The Time Has Come to Say Goodbye

William D. Schlaff, M.D.a and Charles C. Coddington, M.D.b
a

Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson
University, Philadelphia, PA 19107
b

Department of Obstetrics and Gynecology, Carolinas Medical Center, Atrium Health, Charlotte, NC

The evaluation of amenorrhea, whether primary or secondary, has long been inconsistent, confused, or
both for many practitioners. As we consider diagnostic paradigms commonly pursued today, it is useful
to consider the genesis as well as the longstanding applicability and value of the commonly employed
progestin challenge test. To our knowledge, the progestin challenge test became a widely used and
standard diagnostic test following publication of a textbook, Clinical Gynecologic Endocrinology and
Infertility, by Drs. Speroff, Glass, and Kase in 1973 (1). This team of reproductive endocrinologists made
a profound contribution to clinicians by describing an organized, ‘‘compartmentalized’’ approach to the
diagnosis of amenorrhea. One of the key components of this diagnostic cascade was the administration
of a progestational agent which would be expected to induce secretory transition of an estrogenized
endometrium and produce withdrawal vaginal bleeding in women whose uterovaginal anatomy was
normal and intact. The presence of bleeding was (and continues to be) indicative of chronic,
estrogenized anovulation. Conversely, the absence of bleeding in nonpregnant patients was to be
interpreted as reflective of hypoestrogenism, an abnormal or congenitally absent outflow tract, or (left
unsaid) failure of the patient to take the medication.
As we reflect on the clinical context in which the progestin challenge test became the standard approach
in the evaluation of amenorrhea, we should be mindful of the diagnostic tools available to our clinical
leaders in the late 1960s and 1970s. Hormonal assays were much less sensitive and clinical laboratories
performed them far less frequently compared to what we now expect. To think that a folliclestimulating hormone or estradiol value would be back within 90 minutes of a patient leaving the office
would not have crossed the mind of any physician. Clinical use of ultrasound was barely beginning, and
the notion that a real time ultrasound could be performed (never mind interpreted with confidence
about its accuracy) would have been wishful thinking, if not frank fantasy. In this context, we can
understand the relative simplicity of the patient’s trek to her local pharmacy where she presumably
could fill her prescription for a progestin without computerized validation of her prescription plan,
determination of co-pay, and documentation of the universe of adverse effects that could result from
the medication. Further, after taking the medication for 5 days, waiting 2 to 7 days for bleeding to occur
(or not), and then making an appointment for a follow-up consultation (without needing a referral or
additional co-pay), she would have a good idea of what needed to be done either diagnostically or
therapeutically— all within 3 to 4 weeks. If the patient did not have bleeding (for the moment ignoring
the diagnostic dilemma of ‘‘just a little spotting’’), the next recommendation would be to treat with
estrogen for approximately 21 days, adding progestin during the last 5, and awaiting bleeding to
determine if functional endometrium was present. The absence of withdrawal bleeding would then

trigger further testing which would have to be deferred for an additional 2 to 3 weeks to escape the
impact of exogenous hormones on the validity of gonadotropin measurement.
This diagnostic approach continues to be in wide, and arguably standard use today as well. It is timely to
consider more contemporary options. Our ability to take an accurate history or perform an examination
to help direct our diagnostic approach is no better today than it was then; hopefully it is as good. On the
other hand, we can certainly reach the initial diagnostic stage much more expeditiously with a
straightforward transvaginal ultrasound following a history and physical exam. Most clinicians, not to
mention their advance practice providers or ultrasonographers, can easily determine the endometrial
thickness and pattern in a matter of minutes. In most cases, this will allow a rapid and highly accurate
assessment of estrogenization. In more complex cases in which an outflow tract abnormality or
intrauterine synechiae are suspected, the clinician can often make a tentative if not firm diagnosis by
performing the ultrasound her/himself. If the degree of estrogenization is minimal or unclear,
gonadotropin and/or other diagnostic hormonal tests can be ordered at the time of the initial visit.
Conversely, administering a progestin as an initial diagnostic step will not only produce more
inconvenience, it will necessitate a waiting period of at least 10 to 14 days for results. If there is no
bleeding or the initial results are inconclusive, diagnosis will be delayed a further two to six weeks for
lab tests or administration of estrogen plus progestin. Clearly there is a cost for a limited ultrasound, but
there is also a real cost of medications, inconvenience, repeated office visits, and unnecessary delays in
diagnosis if one elects to perform a progestin challenge test.
To be fair, we respect that the description and interpretation of the progestin challenge test have
evolved in ensuing editions of Clinical Gynecologic Endocrinology and Infertility. Nevertheless, we feel
that it is time to largely abandon this approach as an initial diagnostic tool in the evaluation of
amenorrhea. We propose that a directed history and examination, limited ultrasound, and focused
laboratory evaluation at the initial visit should be the standard approach.
In the Preface to the 1st edition of Clinical Gynecologic Endocrinology and Infertility [and quoted in the
Preface to the 7th edition (2)], the authors acknowledged that physicians often feel uncomfortable
when confronted by endocrine problems. They attributed this unease to challenges in knowledge and
approach, both of which they suggested have been improved by the explosion of scientific information
to which they themselves have contributed in a profound way. The authors cautioned that physicians
should avoid attempting to overcome their difficulty ‘‘by mastering a ritualistic series of steps to follow
for each presenting symptom’’ (2) and encouraged us to avoid rigidity in our approach to individual
patients. Certainly, Dr. Speroff accomplished this educational goal in each of the eight editions of this
iconic text, the last two of which he published with our esteemed colleague and friend, Dr. Marc Fritz in
2013. Indeed, his extraordinary contributions were recognized by the updated title of the recently
published 9th edition of the text, now called Speroff’s Clinical Gynecologic Endocrinology and Infertility,
authored by Drs. Hugh Taylor, Lubna Paul, and Emre Seli (3). In proposing that it is time to say goodbye
to the progestin challenge test as a diagnostic tool, we do so with profound admiration and respect for
Dr. Speroff. Indeed, if there were a Mount Rushmore of reproductive endocrinologists he would no
doubt be one of the faces at which we would gaze. We offer our suggestion in the same spirit of
embracing change based on increased scientific information and technology, unburdened by ritualistic
devotion.
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